ME Therapeutics Holdings Inc. (CSE:METX)

ME Therapeutics Holdings Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Net Income	-1.29	-6.52	-0.15
Depreciation & Amortization	0	0	0
Stock-Based Compensation	0.7	0.62	0.01
Other Operating Activities	-	5.55	0.01
Change in Accounts Payable	-0.06	0.06	-0
Change in Other Net Operating Assets	-0	-0.02	-0.01
Operating Cash Flow	-0.66	-0.3	-0.14
Cash Acquisitions	-	0.76	-
Investing Cash Flow	-	0.76	-
Short-Term Debt Issued	-	-	0.14
Total Debt Issued	-	-	0.14
Short-Term Debt Repaid	-0.04	-	-
Total Debt Repaid	-0.04	-	-
Net Debt Issued (Repaid)	-0.04	-	0.14
Issuance of Common Stock	1.56	0.12	-
Other Financing Activities	-0.01	-	-
Financing Cash Flow	1.51	0.12	0.14
Net Cash Flow	0.85	0.57	0
Levered Free Cash Flow	-0.22	0.07	-
Unlevered Free Cash Flow	-0.22	0.08	-
Change in Net Working Capital	0.06	-0.07	-

Updated Jan 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.